GlassScriptPhysician profile
Bernadette S Hee
NPI 1902839806
$2,851.75
in general payments reported to CMS, 2019-2025
28 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,626 · 2020: $349 · 2021: $32.17 · 2022: $32.48 · 2023: $115 · 2024: $348 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.08 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.75 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $437.00 | 2019-2024 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $372.86 | 2019-2023 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $237.78 | 2019-2020 | |
| Novo Nordisk INC | $205.99 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Insmed, INC. | $179.62 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $174.27 | 2019-2025 | Prolastin-C Liquid |
| Philips North America LLC | $81.54 | 2019-2024 | (Ak6) Vest Therapy |
| Jazz Pharmaceuticals INC. | $78.77 | 2019-2020 | |
| Shire North American Group INC | $65.02 | 2019 | |
| Mylan Specialty L.P. | $51.56 | 2019-2020 | |
| Pfizer INC. | $50.93 | 2019 | |
| Lilly USA, LLC | $50.52 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $47.28 | 2019 | |
| Genentech USA, INC. | $47.22 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.22 | 2023 | Glassia |
| Amgen INC. | $35.20 | 2024 | Otezla, Repatha |
| Genzyme Corporation | $21.18 | 2019 | |
| United Therapeutics Corporation | $20.61 | 2021 | |
| Pulmonx Corporation | $20.04 | 2019 | |
| Portola Pharmaceuticals, LLC | $19.82 | 2020 | |
| Ardelyx, INC. | $17.29 | 2024 | Ibsrela |
| Exact Sciences Corporation | $16.74 | 2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $16.31 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.72 | 2025 | |
| Merck Sharp & Dohme LLC | $14.66 | 2019 | |
| Electromed, INC. | $14.29 | 2019 | |
| Circassia INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Hee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.